Streetbeat News

Stock Prices

HAIN

Hain Celestial Group's Q4 EPS exceeded expectations, leading to an 8.20% premarket stock surge. Despite missing revenue estimates and a decline in net sales, the company forecasts stable or improved organic net sales and gross margin growth for FY25.

Portfolio Pulse from Nabaparna Bhattacharya

August 27, 2024 | 12:34 pm

DCTH

Delcath Systems published a study in the Annals of Surgical Oncology showing that their HEPZATO KIT offers improved survival outcomes for metastatic uveal melanoma patients compared to other therapies. The study highlights better overall survival and progression-free survival rates when used as both first-line and second-line therapy.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:34 pm

BUSE

The trading halt status was updated at 8:25 AM ET, indicating a quotation resumption. This update is crucial for investors tracking the affected stocks.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:25 pm

HUMA

Humacyte, Inc. presented positive long-term results for its acellular tissue engineered vessel (ATEV) used in treating vascular injuries in a military setting. The study showed a 12-month patency rate of 87.1% with no infections, amputations, or deaths, highlighting the potential of ATEV in severe wartime injuries.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:16 pm

AAMC

Altisource Asset Management Corp (AAMC) shares dropped 43.6% after announcing plans to voluntarily delist from the NYSE American due to non-compliance with listing standards and to save costs. The delisting is expected to take effect by September 16.

Portfolio Pulse from Henry Khederian

August 27, 2024 | 12:14 pm

CNTA

Centessa Pharmaceuticals announced that its preclinical data for ORX142, a drug targeting excessive daytime sleepiness, will be presented at Sleep Europe 2024. The data shows promising results in non-human primates.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:13 pm

LLY

Eli Lilly has introduced cheaper vials of its weight-loss drug Zepbound, priced up to 50% lower than other incretin medicines, to increase accessibility. The vials are available for self-pay patients with a valid prescription, expanding supply in response to high demand.

Portfolio Pulse from Vandana Singh

August 27, 2024 | 12:13 pm

AMBA

Ambarella, Inc. (NASDAQ:AMBA) is set to release its second-quarter earnings, with analysts expecting a loss of 19 cents per share and revenue of $62.1 million. The stock recently closed at $51.15, up 2.6%. Analysts have varied ratings, with price targets ranging from $50 to $85.

Portfolio Pulse from Avi Kapoor

August 27, 2024 | 12:12 pm

AMWD

CAVA

CGC

GOTU

HIMS

PARA

WTO

American Woodmark Corporation reported disappointing quarterly results, missing both earnings and sales estimates, leading to a 6.4% drop in pre-market trading. Other stocks like CAVA Group, Gaotu Techedu, Hims & Hers Health, Canopy Growth, Paramount Global, and UTime Limited also saw declines in pre-market trading.

Portfolio Pulse from Avi Kapoor

August 27, 2024 | 12:12 pm

LMT

TGLS

Two industrial stocks, Tecnoglass Inc (TGLS) and Lockheed Martin Corp (LMT), are considered overbought with RSI values above 70. Despite strong financial results and strategic deals, investors may want to reconsider holding these stocks due to potential short-term price corrections.

Portfolio Pulse from Avi Kapoor

August 27, 2024 | 12:11 pm